Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11295679 | 0.92 | TDP1 (0.56) | TDP1MAPTMEN1KMT2APOLB | |
| SCHEMBL12798874 | 0.86 | TDP1 (0.62) | TDP1MAPTMEN1KMT2APOLB | |
| SCHEMBL2647110 | 0.84 | SKP2 (0.56) | TDP1MAPTMEN1KMT2APOLB | |
| SCHEMBL11292592 | 0.83 | TDP1 (0.58) | TDP1MAPTMEN1KMT2APOLB | |
| SCHEMBL5869144 | 0.83 | TSHR (0.51) | TDP1MAPTMEN1KMT2APOLB | |
| SCHEMBL992165 | 0.81 | TDP1 (0.61) | TDP1MAPTMEN1KMT2APOLB | |
| SCHEMBL6365845 | 0.81 | KCNH2 (0.51) | TDP1MAPTMEN1KMT2APOLB | |
| SCHEMBL9100894 | 0.81 | KCNH2 (0.51) | TDP1MAPTMEN1KMT2APOLB | |
| SCHEMBL10780618 | 0.81 | KCNH2 (0.51) | TDP1MAPTMEN1KMT2APOLB | |
| SCHEMBL11295215 | 0.81 | MAPT (0.49) | TDP1MAPTMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303782-A1 | PROCESS FOR PREPARATION OF ALBENDAZOLE | SEQUENT SCIENTIFIC LIMITED (IN) | 2013-11-14 | — | — | US | disclosed |
| EP-2643304-A2 | A PROCESS FOR PREPARATION OF ALBENDAZOLE | Sequent Scientific Ltd. (IN) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012070069-A2 | A PROCESS FOR PREPARATION OF ALBENDAZOLE | SEQUENT SCIENTIFIC LIMITED (IN) | 2012-05-31 | — | — | WO | disclosed |
| US-6232331-B1 | TOLERANCE RESISTANT NITRIC OXIDE DONORS IN TREATMENT OF ANGINA PECTORIS | TORRENT PHARMACEUTICAL LTD. (IN) | 2001-05-15 | — | — | US | disclosed |
| EP-0004606-B1 | PROCESS FOR PREPARING ANILINE COMPOUNDS | ETHYL CORPORATION (US) | 1982-03-10 | — | — | EP | disclosed |
| US-4186147-A | DISPLACEMENT OF THIOCYANOANILINE WITH AN ALCOHOL TO FORM THIOALKYL ANILINE | ETHYL CORPORATION (US) | 1980-01-29 | — | — | US | disclosed |
| EP-0004606-A2 | Process for preparing aniline compounds | ETHYL CORPORATION (US) | 1979-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303782-A1 | PROCESS FOR PREPARATION OF ALBENDAZOLE | CPS1, PNPO, NAT1 | TDP1 3997/4885MAPT 3557/4885MEN1 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.